Jefferies Financial Group Inc. Makes New $31.04 Million Investment in Ultragenyx Pharmaceutical Inc. $RARE

Jefferies Financial Group Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 929,626 shares of the biopharmaceutical company’s stock, valued at approximately $31,040,000. Jefferies Financial Group Inc. owned about 0.94% of Ultragenyx Pharmaceutical as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Parallel Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,440 shares during the period. Leonteq Securities AG grew its stake in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,333 shares during the period. Versant Capital Management Inc increased its holdings in shares of Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares in the last quarter. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $39,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,845 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $26.26 on Friday. The stock has a market capitalization of $2.59 billion, a price-to-earnings ratio of -4.50 and a beta of 0.35. Ultragenyx Pharmaceutical Inc. has a one year low of $18.29 and a one year high of $39.89. The business’s fifty day moving average is $28.59 and its 200-day moving average is $25.03.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the prior year, the business earned ($1.17) earnings per share. The firm’s revenue for the quarter was up 28.5% on a year-over-year basis. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -3.99 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the transaction, the director directly owned 21,095 shares of the company’s stock, valued at $528,429.75. This represents a 8.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the sale, the chief financial officer owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,552 shares of company stock worth $207,455 over the last three months. 5.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

RARE has been the topic of a number of recent research reports. Royal Bank Of Canada raised their target price on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Monday, August 10th. Guggenheim dropped their price objective on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Finally, Morgan Stanley lifted their price objective on shares of Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the stock an “overweight” rating in a report on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.22.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.